---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-028451"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:37:33.751938+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience Q2 revenue up 116% to $316K; closes WFI acquisition for $10M

## Summary
- Revenue $315,902 (+116% YoY); clinic revenue $254,364 (+126%); all clinics $712,433 (+145%).
- Acquired Wisconsin Fertility Institute for $10M (3-yr payment); WFI 2022 rev $5.4M, net income $1.7M.
- Adjusted EBITDA -$1.6M (vs. -$2.2M); cash $0.1M at 6/30; $4.5M raised in public offering post-Q.
- Expects clinic ops cash flow positive in Q3 2023, overall operating cash flow positive in 2024.
- Received FDA 510(k) clearance for expanded use of INVOcell device.

## SEC filing metadata
- accession: 0001493152-23-028451
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/0001493152-23-028451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-028451
- JSON: https://secwatch.observer/filing/0001493152-23-028451.json
- Plain text: https://secwatch.observer/filing/0001493152-23-028451.txt

## Key facts
- Earnings Releases
  INVO Fertility, Inc. reported the second quarter ended June 30, 2023 results: revenue $315,902.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $315,902
  - Result: reported results
  source text: for the second quarter ended June 30, 2023 and provided a business update. Q2 2023 Financial Highlights (all metrics compared to Q2 2022 unless otherwise noted) ● Revenue was $315,902, an increase of 116% compared to $146,135. ● Clinic revenue increased 126% to $254,364, compared to $112,358. All reported clinic revenue is derived from the Company’s INVO
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/0001493152-23-028451-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.